Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Captopril vs Empagliflozin: Empagliflozin has the stronger overall evidence (4.5 vs 3.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Empagliflozin wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Captopril and Empagliflozin have evidence — compare verdict strength side-by-side.
Off-label longevity use mirrors low antihypertensive dosing (captopril is short-acting; longer-acting ACE inhibitors like lisinopril/ramipril are often used) under a clinician. Not an approved longevity regimen; blood pressure and potassium should be monitored.
any
Oral tablet (or a longer-acting ACE inhibitor)
Off-label use mirrors approved dosing (10–25 mg once daily in the morning) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (empagliflozin)
Unknown in humans
Months to years
Years
Throughout use
Months to years
Months to years
Weeks to months
Throughout use
Angiotensin Converting Enzyme (ACE) Inhibitor Extends Caenorhabditis elegans Life Span.
PLoS genetics (2016) · Animal
ACE inhibition extended lifespan in the worm C. elegans
The ACE inhibitor captopril inhibits ACN-1 to control dauer formation and aging.
Development (Cambridge, England) (2024) · Animal
Captopril specifically inhibits the worm ACE homolog ACN-1
Control of aging by the renin-angiotensin system: a review of C. elegans, Drosophila, and mammals.
Frontiers in pharmacology (2022) · Review
Review framing RAS/ACE modulation as a conserved aging pathway
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial in high-CV-risk type-2 diabetics
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation (2018) · Rct
Randomized evidence of empagliflozin benefit in established cardiovascular disease
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2023) · Rct
EMPA-KIDNEY randomized trial in a broad chronic-kidney-disease population
Empagliflozin has a higher evidence score (4.5/10 vs 3.5/10) and wins in 2 of 3 categories.
For support heart health, Empagliflozin has a higher relevance score (72 vs 62).
No known interactions between Captopril and Empagliflozin have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.